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Background: To understand the involvement of structural maintenance of chromosome 4 (SMC4) in the
development and progression of hepatocellular carcinoma (HCC).
Methods: Real-time quantitative PCR and Western Blotting were applied to measure the expression of SMC4 in
HCC samples and cell lines. The tumor-promoting effect of SMC4 was determined by WST-1, soft agar colony
formation, cell motility and invasion assays. The SMC4 target signal pathway was identified by luciferase reporter
and real-time quantitative PCR assays.
Results: The upregulation of SMC4 was frequently detected in HCC samples and cell lines. Functional assays
demonstrated that SMC4 could effectively promote tumor cell growth rate, colony formation in soft agar,
wound-healing and invasion. Further studies showed that increased miR-219 levels caused a significant decrease in
the SMC4 expression, and SMC4 inhibitor downregulated JAK2/Stat3 expression at both the mRNA and protein levels.
Conclusions: Our findings provide new insight into SMC4 function and the mechanisms of growth and
invasion of HCC.
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Hepatocellular carcinoma (HCC) is the most common
primary liver cancer, and the third most deadly type of
cancer globally, following lung and stomach cancers [1].
With more than 750,000 new cases diagnosed every year
worldwide, HCC is the sixth most common neoplasm
[2,3]. There is considerable controversy about the role of
surveillance in its management [4]. Small HCCs are
amenable to more effective treatment [5,6]. However,
HCC is diagnosed at advanced stages in most patients
when only limited therapeutic options are available.
From a molecular perspective, HCC is a highly hetero-
geneous tumor [7]. Increasing evidence suggests that its
complexity and clinical variability mainly depend on
various molecular alterations that arise during the de-
velopment and progression of this disease [7-10]. Previ-
ous studies have reported on aberrant activation of
various cellular pathways such as GSK-3 beta-C/EBP
alpha-miR-122-Insulin Growth Factor 1 Receptor [11],* Correspondence: chenpingsyd@126.com
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unless otherwise stated.HDGF-related protein-3 [12], FoxM1/ACP5 [13], JAK/
STAT [14], miR-219-5p/glypican-3 [15] etc. Moreover,
recent studies have demonstrated the importance of the
JAK/STAT pathway in the development of HCC, and
suggest that the use of JAK/STAT inhibitors might have
potential in the treatment of HCC [16]. miR-219 has
been shown to exert tumor-suppressive effects during
hepatic carcinogenesis through negative regulation of
GPC3 expression [15]. Therefore, identification of the
predominant molecular mechanisms as therapeutic op-
tions for HCC is a research area of great importance
and interest.
In a previous study, we demonstrated that structural
maintenance of chromosome 4 (SMC4) is highly expressed
in human HCC tissues and cell lines. We further showed
that expression of SMC4 may be useful for the early detec-
tion of HCC, and is related to the progression and invasion
the tumor [17]. In the current study, we aimed to provide
new insight into SMC4 function, and the mechanisms
of growth and invasion of HCC.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Cell lines and clinical samples
Human hepatocellular carcinoma 97-H, HepG2, Bel-7405,
and smmc-7721 cell lines and human normal liver L02
(also called HL-7702) cell line ,were purchased from
Chinese Academy of Sciences (Shanghai, China). A total
of 72 HCC samples from primary tumor, paracancerous
samples and adjacent non-tumor sites were obtained from
patients with primary liver cancer prior to any therapy.
Written informed consent from all patients was obtained
prior to participation in the study. The adjacent non-
tumor area was subsequently verified by histology to
be free of tumor infiltration. Clinical samples were ob-
tained from Department of Hepatobiliary Surgery, Daping
Hospital and Research Institute of Surgery, the Third
Military Medical University between September 2009 and
December 2010. All samples were immediately snap-frozen
and kept at −80°C until use. This study was approved
by the Ethics Committee of Daping Hospital and Research
Institute of Surgery, the Third Military Medical University,
Chongqing, China. (#ChiCTR- DDT-11001845).
Real-time quantitative PCR
Total RNA was extracted from cultured cells or frozen tis-
sues using TRIzol reagent (Invitrogen, Carlsbad, California,
USA), and RNA was reverse-transcribed by an RT-PCR
kit (Invitrogen, Carlsbad, California, USA) according to
the manufacturer’s instructions. Quantitative PCR was
then carried out with primers for miR-219, SMC4, JAK2,
and Stat3 with SYBR Green PCR Master Mix (Invitrogen,
Carlsbad, California, USA) in a real-time PCR System
(Applied Biosystems, Carlsbad, California, USA) following
standard quantitative PCR procedure [18]. Primers are
shown in Table 1. SMC4, JAK2, and Stat3 levels were ana-
lyzed. The programs were as follows: PCR mixtures were
denatured at 95°C for 5 min, followed by 40 cycles of 94°C
for 20 s, 61°C for 20 s, and 72°C for 20 s, and a final exten-
sion at 72°C for 5 min, 55°C for 10 s. miR-219 was ana-
lyzed as follows: PCR mixtures were incubated at 95°C for
5 min, followed by 40 cycles with incubation at 95°C for




mir-219 5'- TGATTGTCCAAACGCA -3'
U6 5'- CTCGCTTCGGCAGCACA -3'
JAK2 5'- AGCCTATCGGCATGGAATATCT
STAT3 5'- ACCAGCAGTATAGCCGCTTC -3'
β-actin 5'- CATTAAGGAGAAGCTGTGCT-3'the geometric mean of the housekeeping gene, β-actin
and U6 (Sangon Biotech, Shanghai, China) as the control.
Western Blotting
Total protein was extracted from cultured cells or fro-
zen tissues using total protein extraction kit (ProMab
Biotechnologies, Richmond, USA) according to the manu-
facturer’s instructions. Protein extracts were separated on
10% SDS-PAGE gels and electrophoretically transferred to
nitrocellulose membranes at 300 mA for 70 min. The
membranes were incubated with the following antibodies
and dilutions: the rabbit anti-SMC4, rabbit anti -JAk2 and
rabbit anti-Stat3 at dilutions of 1:500 (Abcam, Cambridge,
UK), and goat anti rabbit secondary antibody at a dilution
of 1:4000 (Abcam, Cambridge, UK). The nitrocellulose
membranes were exposed to X-ray films to detect the
positive protein band. GAPDH (Santa Cruz Biotechnologies,
CA, USA) was used as the control.
Construction of vector and transfection
To knockdown SMC4 expression, we first designed and
synthesized 3 pairs of siRNA fragments (GenePharma,
Shanghai, China), and one pair of a negative control
(GenePharma, Shanghai, China). Previous studies have
shown that SMC4-Homo-830 (Table 2) greatly decreased
SMC4 expression [17]. SMC4-Homo-830 was cloned into
Pgpu/GFP/ Neo-shNC vector (GenePharma, Shanghai,
China), and transfected into 97-H and HepG2, HCC cell
lines. MiR-219 mimics and miR-219 inhibitor were pur-
chased from Shanghai GenePharma Co., Ltd (Table 3).
SMC4-Homo-830, miR-219 mimics and miR-219 inhibitor
were then stably and transiently transfected into 97-H and
HepG2 cells using Lipofectamine 2000 (Invitrogen).
Cell motility and invasion assay
Wound-healing assay and invasion assay were performed
as described previously [19]. For wound healing assay,
the cell layer was wounded using a sterile micropipette
tip. The spread of wound closure was observed for 72 h
after transfection, and photographed under a microscope.





-3' 5'- TAACACTGCCATCCCAAGACA -3'
5'- GCCACAATCCGGGCAATCT -3'
5'- GTTGAAGGTAGTTTCGTGGA -3'
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and coated with a layer of extracellular matrix (Beyo-
time Institute of Biotechnology, Shanghai, China) ac-
cording to the manufacturer's instructions. After 72 h of
transfection, the number of cells that penetrated the
matrigel was counted from 5 randomly selected fields (left,
right, up, down and middle).
WST-1 and soft agar colony formation assays
For WST-1 assays, cells were plated in 96-well culture
plates (0.1-5 × 104/ml), and incubated for 0–72 h after
transfection with 10 μl WST-1/ECS. The wells with
WST-1/ECS (Beyotime Institute of Biotechnology, Shanghai,
China), and without cells as the blank control were in-
cubated for 2 h. The wells were measured at 450 nm.
Experiments were repeated three times independently.
For colony formation assays, 0.3% of the superstratum
agar, 0.6% low melting point agarose and cell cultures
were mixed in equal volumes. To each well was added
1 ml of superstratum agar and 100 μl single cell suspen-
sion(about 1000 cell/well), and incubated for 2 weeks at
37°C and 5% CO2.
Luciferase Reporter Assay
Luciferase reporter assays were used to characterize the
miR-219 promoter and SMC4 -targeted 3’-UTR activity.
Stable miR-219 mimics and miR-219 inhibitor (97-H
and HepG2) were transfected with the reporter constructs
(Additional file 1). The luciferase activity was measured
by a luciferin enzyme detection assay kit (Promega,
Wisconsin, USA).
Co-immunoprecipitation
97-H and HepG2 cells were collected, and total protein
was extracted in RIPA buffer. Cell lysates were centri-
fuged and the pellets discarded. Protein lysates were in-
cubated with 2 μg Stat3 antibody (1:150) overnight
followed by 20 μl Protein A + G Agarose and incubated




AAUUGCGUUUGGACAAUCAUU-3'the immunoprecipitate was washed with 1 ml PBS. Load-
ing buffer, 20 μl, was added to the immunoprecipitated
protein and boiled for 5 min followed by SDS-PAGE, and
Western Blotting.
Statistical analysis
Statistical analysis was carried out using SPSS 16.0 for
Windows. Student’s t-test was used to analyze the results
expressed as mean ± SD. Correlation analysis was used
to analyze the relationship between miR-219 and SMC4.
Differences were considered significant when the p values
were less than 0.05.
Results
SMC4 is strongly upregulated in HCC
Real-time quantitative PCR and Western Blotting were
performed to determine the expression of SMC4 in 4
HCC cell lines (97-H, HepG2, Bel-7405, and smmc-
7721) and 4 primary HCC samples. The results showed
that SMC4 was strongly upregulated in 4 HCC cell lines
compared to normal cells (L02), and highly expressed in
4 primary HCC samples compared to paracancerous and
non-tumor samples (Figure 1).
SMC4 facilitates tumor cells proliferation, invasion and
migration
To explore the potential role of SMC4 in HCC, SMC4-
homo-830 was cloned and stably transfected into cell
lines (97-H and HepG2) and compared with controls.
Cellular proliferation evaluated by soft agar colony for-
mation assays showed that colony formation in soft agar
was significantly inhibited in experimental groups com-
pared with normal controls (Figure 2A). WST-1 assays
also showed that the cell growth of 97-H and HepG2
cell lines were also significantly suppressed from 100%
to 73.4% and 60.9% separately (Figure 2B). To further
study the invasion and migration ability of SMC4,
wound-healing and invasion assays were also performed.
Wound-healing assays showed that cell migration rate
was reduced compared with the empty vector-
transfected and non-transfected groups (Figure 2C).
Cell invasion assays also indicated that the number of
invasive cells was significantly decreased (Figure 2D).
However, statistical analysis demonstrated a significant
difference in the association between experimental groups
compared with normal controls (P < 0.05). Therefore, we
conclude that SMC4 can promote the tumor cell prolifera-
tion, invasion and migration.
Regulation of SMC4 Transcription by miR-219
Using five different bioinformatics software (TargetScan,
miRDB, picTar, DIANA microRNA) to analysis 3’UTR of
Figure 1 Upregulation of SMC4 in HCC. (A) Expression observed in 4 primary HCC samples (T) compared to paracancerous (P) and non-tumor
(N) as determined by real-time quantitative PCR. (B) Expression observed in 4 HCC cell lines (97-H, HepG2, Bel-7405, and smmc-7721) compared
to normal cells (L02) as determined by real-time quantitative PCR. (C) Expression observed in 4 primary HCC samples (T) compared to paracancerous
(P) and non-tumor tissues (N) by Western Blotting. (D) Expression observed in 4 HCC cell lines (97-H, HepG2, Bel-7405, and smmc-7721) compared to
normal cells (L02) by Western Blotting.
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(Figure 3A). Quantitative PCR analysis demonstrated
that miR-219 was significantly downregulated, which
was consistent with the data from HCC tissues and cell
lines (Figure 3B). We evaluated the effect of miR-219
levels on SMC4 transcription. After the miR-219 mimics
and miR-219 inhibitor were transfected into the 97-H
and HepG2 cell lines, real-time quantitative PCR, and
Western Blotting assays showed that miR-219 silencing
caused a significant increase in SMC4 expression. MiR-
219 overexpression caused a significantly decrease in
the SMC4 expression in 97-H and HepG2 cell lines
(Figure 3C and 3D). Luciferase reporter assays also con-
firmed a negative regulation relationship between miR-219
and SMC4 (Figure 3E).JAK2/Stat3 is the potential target of SMC4
By searching the potential targets of SMC4 with PIPs
and Donime [20,21], JAK2/Stat3 was identified as the
target of SMC4. Quantitative PCR and Western Blotting
showed that JAK2/Stat3 was strongly upregulated at
both RNA and protein levels (Figure 4A and Figure 4B).
After the SMC4 inhibitor was transfected into the 97-H
and HepG2 cell lines, real-time quantitative PCR and
Western Blotting showed that SMC4 downregulated
JAK2/Stat3 expression at both RNA and protein levels
(Figure 4C). Co-immunoprecipitation was used to detect
the phosphorylating modification of Stat3. The results
indicated that p-Stat3 (Tyr705) protein expression
decreased significantly after silencing of SMC4, and
p- Stat3(Ser727)had no significant changes (Figure 4D).
Figure 2 SMC4 tumor-promoting effects (×400). (A) Colony formation in soft agar after exposure to SMC4-homo-830. Representative images
were taken at time 72 h after transfection. (B) Cell growth rates after exposure to SMC4-homo-830 as detected by WST-1 assay. (C) Wound-healing as-
says and cell motility after exposure to SMC4-homo-830. Representative images were taken at time 72 h after scratching. (D) SMC4-homo-830
decreased tumor cell invasion activity of 97-H and HepG2 cells. (*p < 0.05).
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of p- Stat3 occurred at amino acid Tyr705, but not
Ser727. After the miR-219 mimics, and miR-219 inhibi-
tor were transfected into the 97-H and HepG2 cell lines,
Western Blotting results showed that miR-219 silencing
caused a significant increase in JAK2/Stat3 expression.
miR-219 overexpression caused a significant decrease in
the JAK2/Stat3 expression in 97-H and HepG2 cell
lines. The results also indicated that p-Stat3 (Tyr705)
protein expression changed significantly after modula-
tion with miR-219, while p-Stat3(Ser727) had no signifi-
cant changes (Figure 4E).Discussion
Structural maintenance of chromosomes (SMC) proteins
are chromosomal ATPases, and are highly conserved
from bacteria to humans. They play fundamental roles in
many aspects of higher-order chromosome organization
and dynamics [22]. SMC proteins act as global organizers
and safeguards by directly and indirectly influencing
chromosome structure and dynamics. They participate
in a vast number of vital cellular processes ranging from
cell division to gene regulation and DNA repair [23]. In-
dividual eukaryotic organisms have at least six SMC
family members that form three heterodimers in specific
Figure 3 SMC4 is a downstream target of miR-219. (A) The predicted binding sequence of SMC4 and its binding site in the 3’-untranslated
region (UTR) of SMC4 (sense) is presented for alignment. (B) Real-time quantitative PCR results showing miR-219 levels in HCC tissues and cell
lines (T, HCC tissues; P, paracancerous tissues; N, non-tumor tissues). (C) Real-time quantitative PCR result showing that SMC4 upregulation by
miR-219-inhibit, and also downregulation by overexpression of miR-219 in 97-H and HepG2 cell lines. (D) Western Blotting result showing that
SMC4 upregulation by miR-219-inhibit, and also downregulation by overexpression of miR-219 in 97-H and HepG2 cell lines (1,97-H/HepG2;
2, 97-H/HepG2-vector; 3, 97-H/HepG2-minics; 4, 97-H/HepG2-inhibitor). (E) Luciferase reporter assays were used to confirm the interaction of miR-219
with SMC4. 3’-UTR of SMC4 containing the target binding site (sense) was cloned downstream of a firefly luciferase gene. The plasmids were
transfected into empty vector and miR-219 stably expressing cells (97-H, HepG2).
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SMC2 and SMC4. SMC2 and SMC4 that are central
components of condensin complexes [24]. SMC4 en-
codes a “structural maintenance of chromosomes” pro-
tein, and is a subunit of condensin. It has clear roles in
chromosome condensation and mitosis, and is required
for normal S phase progression, indicating a previously
unrecognized role of Smc4p in the synchronous pro-
gression from G1 into S phase [25,26]. Research also
suggests that SMC4 is a potential biomarker of the sen-
sitivity of breast cancer cells to paclitaxel and the re-
sponse to SAHA/paclitaxel combination treatment [27].
Previous studies have shown that the expression of SMC4mRNA and protein was highly upregulated in HCC tissues
and cell lines. Levels of SMC4 protein were significantly
associated with tumor size, differentiation, TNM stage,
and vascular invasion of primary liver cancer [17]. From
data presented on these 72 cases published previously, the
4 specimens selected in the current study are representa-
tive of the others. In the present study, we also found that
SMC4 was frequently upregulated in HCC cases and cell
lines, consistent with our previous study. Therefore, we
assumed that SMC4 played an important role in HCC de-
velopment and invasion. In the current study, the effects
of SMC4 on HCC development and invasion were investi-
gated. One important task was to identify the upstream
Figure 4 JAK2/Stat3 is downstream target of SMC4. (A) Real-time quantitative PCR results on JAK2/Stat3 expression in HCC tissues and cell
lines (T, HCC tissues; P, paracancerous tissues; N, non-tumor tissues). (B) Western blotting results showing that JAK2/Stat3 was upregulation in
HCC cell lines (T, HCC tissues; P, paracancerous tissues; N, non-tumor tissues). (C) Western Blotting (left) and real-time quantitative PCR (right)
results showing JAK2/Stat3 downregulation by SMC4-inhibit in 97-H and HepG2 cell lines (1–3, 97-H/HepG2; 4–6, 97-H/HepG2 -vector; 7–9, 97-H/
HepG2-inhibit). (D) Co-immunoprecipitation assays showing that p-Stat3 (Tyr705) protein expression after silencing of SMC4 in 97-H and HepG2
cell lines (1–3, 97-H/HepG2; 4–6, 97-H/HepG2 -vector; 7–9, 97-H/HepG2-inhibit). (E) Western Blotting results showing JAK2/Stat3 changed by after
miR-219 modulation with mimics and inhibitors in 97-H and HepG2 cell lines, and phosphorylation status (1, 97-H/ HepG2; 2, 97-H/HepG2 -vector;
3, 97-H/HepG2-minics; 4, 97-H/ HepG2-inhibitor ). GAPDH was used as a control. (*p < 0.05).
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informatics software to analyze the 3’UTR of SMC4,
miR-219 was found to be involved. A previous studyalso showed that miR-219 was potentially involved in
gastric cancer progression and metastasis [28]. MiR-219
has been found to be significantly downregulated in
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carcinogenesis through negative regulation of GPC3 ex-
pression [15], which is consistent with our experimental
results in HCC cell lines and tissues. Previous studies
have shown that miR-219 inhibited cell proliferation
[29,30]. There are several known pathways, including
the GPC3 pathway by which the proliferation of HCC
cells is regulated. GPC3 is a cell surface protein that has
been implicated as a possible tumor marker for HCC
[31]. In the current study, we found that SMC4 is also a
target of miR-219 in the regulation of the proliferation
and invasion of HCC cells. Correlation analysis showed
that these two indexes had a trend of negative correlation
(r = −0.394, p = 0.000). Quantitative PCR and Western
Blotting analysis also demonstrated that miR-219 decreased
SMC4 mRNA levels. In addition, inhibiting miR-219
expression increased SMC4 levels. Luciferase assays showed
a negative regulatory relationship between miR-219 and
SMC4. Furthermore, we identified the downstream target
regulated by SMC4. JAK2/Stat3 was identified as the tar-
get of SMC4. JAK2, a member of the Janus (JAK) family
of non-receptor protein tyrosine kinases, regulates signal-
ing via multiple cytokine receptors [32,33]. Stat3, which is
associated with oncogenesis, cell proliferation, angiogen-
esis, immune evasion, and apoptotic resistance, is consti-
tutively activated in human HCC tissues, but not in
normal human liver tissues [34-36]. One study showed
that celecoxib decreased Stat3 phosphorylation by redu-
cing Janus kinase (JAK2) phosphorylation, and caused
apoptosis in HCC cells [37]. Peak Stat3 phosphorylation
occurred within 15–60 min of exposure to cytokine. This
constitutive activation of Stat3 is due to deregulation of
protein tyrosine kinases or constitutive release of growth
factors that activate Stat3 [38-40]. Activation of JAK2/
Stat3 signaling in solid tumors may represent a prognostic
biomarker and therapeutic target [41].
In the present study, quantitative PCR and Western
Blotting analysis demonstrated that JAK2/ Stat3 was
significantly upregulated in HCC tissues and cell lines.
Quantitative PCR and Western blotting analysis also
demonstrated that SMC4 increased the expression of
JAK2/ Stat3 at mRNA and protein levels. In addition,
inhibition of SMC4 expression decreased JAK2/Stat3
expression. Phosphorylation of Stat3 has been shown
to occur both at the tyrosine 705 (Y705) and at the
serine 727 (S727) residues in the cytoplasmic tail [42].
Co-immunoprecipitation in the current study showed
that the main change of phosphorylation of p-Stat3 oc-
curred at amino acid Y705, but not at S727. Western
Blotting analysis also showed that miR-219 resulted in
significant changes in JAK2/Stat3 expression. p-Stat3
(Tyr705) protein expression also changed significantly
after modulation with miR-219, but the p-Stat3(Ser727)
had no significant changes.Conclusions
In summary, we have identified a novel miR-219/SMC4/
JAK2/Stat3 signaling pathway whose function may con-
tribute to the development of HCC. Our findings provide
new insight into SMC4 function and the mechanisms of
growth and invasion in HCC.
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